🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ StockGenie AI

Vimta Labs Limited VIMTALABS NSEPHARMA

Healthcare · Diagnostics & Research · India
https://vimta.com

Vimta Labs Limited provides contract research and testing services in India and internationally. The company offers drug discovery, development, and drug life cycle management support services in the areas of preclinical research, clinical research, and analytical services for biopharmaceutical companies; preclinical research and testing services for medical device companies; and contract research and testing for agrochemical and specialty chemical companies. It also provides food testing and analytical development services to support manufacturers, processors, farmers, retailers, traders, exporters, and regulators; and a testing laboratory for water, alcoholic, and non-alcoholic beverages. In addition, the company offers environmental regulatory services, such as impact assessments and post project monitoring, to various industries, including power, infrastructure, cement, oil and gas, and mining, etc.; and EMI/EMC testing for electronic and electrical products/components. It provides solutions to agriculture, biologics and biosimilars, home and personal care, medical device, specialty chemicals, food, electrical and electronics, nutraceuticals, water and beverages, pharmaceuticals, crop care, environment, health and safety, and packaging industries. Vimta Labs Limited was founded in 1984 and is headquartered in Hyderabad, India.

READ MORE ›
₹469.70
-4.18% 1Y

Market & Price

Market Cap
₹2,103.45 Cr
Current Price
₹469.70
High / Low (52W)
₹877.20 / ₹380.70
Beta
-0.18

Valuation

Stock P/E
27.32
Industry PE
37.60
Forward P/E
-
PEG Ratio
-
Book Value
₹93.23
Price to Book
5.04
P/S
5.16
EV/EBITDA
14.36
Dividend Yield
0.43%

Profitability & Returns

ROCE
21.16%
ROE
18.55%
ROA
11.88%
Profit Margin
19.03%
Op Margin
24.37%
EPS (Latest Qtr)
₹4.62
EPS (TTM)
₹17.19

Balance Sheet & Liquidity

Debt/Equity
0.73
Quick Ratio
2.64
Current Ratio
3.43
Debt
₹3.33 Cr
Total Assets
₹562.23 Cr
Current Assets
₹224.87 Cr
Working Capital
₹159.35 Cr

Ownership

Promoter Holding
65.89%
Chg in Prom Hold
-
FII / Inst Holding
4.17%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
₹2,032.84 Cr
Total Revenue (TTM)
₹407.29 Cr
EBITDA
₹141.52 Cr
Free Cash Flow
₹11.69 Cr
Operating Cash Flow
₹147.14 Cr
Shares Outstanding
₹4.47 Cr
Gross Margin
80.16%
Payout Ratio
5.81%

Growth (CAGR)

Revenue 5Y
8.94%
Profit 5Y
17.18%
Revenue (YoY)
14.00%
Earnings (YoY)
18.20%

PROS

  • Healthy ROCE of 21.2%.
  • Profit CAGR of 17.2% over 5 years.
  • Generates positive free cash flow.

CONS

  • Trading 46.5% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

NSE TradingView Screener.in

Fundamental Growth

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 VIMTALABS Vimta Labs Limited NSEPHARMA 469.70 27.32 ₹2,103.45 Cr 0.43% 21.16% 18.55% 8.94% 17.18%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,799.20 37.59 ₹4.32 L Cr 0.92% 17.94% 14.72% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 6,667.00 68.97 ₹1.77 L Cr 0.45% 18.96% 16.19% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,410.80 68.96 ₹1.49 L Cr 0.86% 9.06% 16.98% 13.27% 20.21%
5 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,401.00 29.16 ₹1.13 L Cr 0.93% 14.88% 11.74% 7.23% 11.45%
6 DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA 1,303.50 25.90 ₹1.09 L Cr 0.61% 14.00% 11.83% 10.96% -2.35%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,077.70 21.51 ₹1.08 L Cr 0.09% 19.24% 18.32% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,267.70 19.49 ₹1.04 L Cr 0.53% 28.42% 26.91% 19.10% 131.46%
9 MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA 2,375.60 51.29 ₹98,090.71 Cr 0.08% 13.78% 12.45% 17.73% 14.28%
Ad space

Quarterly Results

Figures in INR.

Metric Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 94.44 Cr97.56 Cr101.85 Cr98.63 Cr109.25 Cr
Cost of Revenue 18.18 Cr18.81 Cr20.15 Cr19.36 Cr22.48 Cr
Gross Profit 76.26 Cr78.75 Cr81.70 Cr79.27 Cr86.77 Cr
Operating Expenses 52.44 Cr54.93 Cr57.71 Cr55.96 Cr60.15 Cr
Operating Income 23.82 Cr23.83 Cr23.99 Cr23.31 Cr26.62 Cr
EBITDA 34.68 Cr35.44 Cr36.89 Cr34.45 Cr42.12 Cr
Interest Expense 43.80 L31.50 L37.40 L15.70 L32.10 L
Pretax Income 25.03 Cr25.26 Cr26.27 Cr23.37 Cr29.05 Cr
Tax Provision 6.71 Cr6.37 Cr6.35 Cr5.79 Cr7.93 Cr
Net Income 18.32 Cr18.89 Cr19.92 Cr17.59 Cr21.11 Cr
Diluted EPS 4.044.214.443.944.62

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue -315.06 Cr288.60 Cr343.98 Cr407.29 Cr
Cost of Revenue -73.85 Cr57.66 Cr71.45 Cr80.79 Cr
Gross Profit -241.21 Cr230.94 Cr272.54 Cr326.50 Cr
Operating Expenses -171.53 Cr166.48 Cr185.88 Cr228.75 Cr
Operating Income -69.68 Cr64.46 Cr86.66 Cr97.75 Cr
EBITDA -96.64 Cr98.22 Cr126.63 Cr148.89 Cr
Interest Expense -92.80 L1.52 Cr1.90 Cr1.17 Cr
Pretax Income -65.00 Cr62.50 Cr89.00 Cr103.95 Cr
Tax Provision -16.82 Cr13.69 Cr22.25 Cr26.44 Cr
Net Income -48.17 Cr41.01 Cr67.34 Cr77.51 Cr
Diluted EPS -10.689.1214.9317.20

Compounded Sales Growth

5 Years:8.94%
1 Year:14.00%

Compounded Profit Growth

5 Years:17.18%
1 Year:18.20%

Stock Price Performance

1 Year:-4.18%
6 Months:-23.58%
3 Months:+1.61%
1 Month:+2.75%

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets -362.32 Cr394.47 Cr466.53 Cr562.23 Cr
Current Assets -163.66 Cr157.60 Cr187.82 Cr224.87 Cr
Cash & Equivalents -30.50 Cr13.44 Cr15.84 Cr22.97 Cr
Inventory -22.62 Cr24.69 Cr25.06 Cr29.95 Cr
Receivables -79.99 Cr87.00 Cr106.24 Cr105.70 Cr
Total Liabilities -80.54 Cr80.35 Cr87.68 Cr105.36 Cr
Current Liabilities -57.28 Cr54.07 Cr64.37 Cr65.52 Cr
Long Term Debt -9.89 Cr9.07 Cr3.22 Cr1.56 Cr
Total Debt -14.99 Cr19.19 Cr8.52 Cr3.33 Cr
Total Equity -281.79 Cr314.12 Cr378.85 Cr456.87 Cr
Shares Outstanding -4.43 Cr4.43 Cr4.45 Cr4.47 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow -87.94 Cr60.89 Cr94.05 Cr147.14 Cr
Investing Cash Flow --57.26 Cr-76.05 Cr-75.54 Cr-129.67 Cr
Financing Cash Flow --10.98 Cr-1.90 Cr-16.12 Cr-10.35 Cr
Capital Expenditure --49.80 Cr-76.57 Cr-79.49 Cr-99.80 Cr
Free Cash Flow -38.13 Cr-15.68 Cr14.56 Cr47.34 Cr
Net Change in Cash -19.70 Cr-17.06 Cr2.40 Cr7.12 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % -76.6%80.0%79.2%80.2%
Operating Margin % -22.1%22.3%25.2%24.0%
Net Margin % -15.3%14.2%19.6%19.0%
ROE % -17.1%13.1%17.8%17.0%
ROCE % -22.8%18.9%21.5%19.7%

Shareholding Pattern

Insiders
65.89%
Institutions
4.17%
Public Float
12.23%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for VIMTALABS

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks